Finance

Lists
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
THB 5.30
+1.92%
(+0.10) 1D
Sep 1, 4:40:00 PM GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for WUXI06...
Open
THB 5.20
High
THB 5.30
Low
THB 5.20
Mkt. cap
205.09B
Avg. vol.
81.89K
Volume
171.28K
52-wk high
THB 5.95
52-wk low
THB 3.02
Shares outstanding
2.50B
No. of employees
15K
Open
THB 5.20
High
THB 5.30
Low
THB 5.20
Mkt. cap
205.09B
Avg. vol.
81.89K
Volume
171.28K
52-wk high
THB 5.95
52-wk low
THB 3.02
Shares outstanding
2.50B
No. of employees
15K
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Employees14.7K
Founded2010
Headquarters-
SectorHealth care
Websitewuxibiologics.com
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
5.92B
5.92B
5.89B
5.89B
Cost of goods sold
3.04B
3.04B
3.17B
3.17B
Cost of revenue
3.04B
3.04B
3.17B
3.17B
Research and development expenses
254.93M
254.93M
215.11M
215.11M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
631.03M
631.03M
591.61M
591.61M
Operating expense
921.71M
921.71M
860.09M
860.09M
Total operating expenses
3.96B
3.96B
4.03B
4.03B
Operating income
1.96B
1.96B
1.86B
1.86B
Other non operating income
33.58M
33.58M
72.05M
72.05M
EBT including unusual items
1.96B
1.96B
1.71B
1.71B
EBT excluding unusual items
1.94B
1.94B
1.70B
1.70B
Income tax expense
476.10M
476.10M
251.54M
251.54M
Effective tax rate
24.24%
24.24%
14.71%
14.71%
Other operating expenses
-
-
-
-
Net income
1.28B
1.28B
1.22B
1.22B
Net profit margin
21.70%
21.70%
20.70%
20.70%
Earnings per share
-
-
-
-
Interest and investment income
115.29M
115.29M
106.38M
106.38M
Interest expense
-29.76M
-29.76M
-52.12M
-52.12M
Net interest expenses
85.53M
85.53M
54.25M
54.25M
Depreciation and amortization charges
-
-
-
-
EBITDA
2.24B
2.24B
2.18B
2.18B
Gain or loss from assets sale
317.34M
317.34M
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps